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Abstract
Objective—We aimed to systematically review available literature linking adipokines to 
gestational diabetes mellitus (GDM) for a comprehensive understanding of the roles of adipokines 
in the development of GDM.
Methods—We searched PubMed/MEDLINE and EMBASE databases for published studies on 
adipokines and GDM through October 21, 2014. We included articles if they had a prospective 
study design (i.e., blood samples for adipokines measurement were collected before GDM 
diagnosis). Random-effects models were used to pool the weighted mean differences comparing 
levels of adipokines between GDM cases and non-GDM controls.
Results—Of 1,523 potentially relevant articles, we included 25 prospective studies relating 
adipokines to incident GDM. Our meta-analysis of nine prospective studies on adiponectin and 
eight prospective studies on leptin indicated that adiponectin levels in the first or early second 
trimester of pregnancy were 2.25 μg/ml lower (95% CI: 1.75–2.75), whereas leptin levels were 
7.25 ng/ml higher (95% CI 3.27–11.22), among women who later developed GDM than women 
who did not. Prospective data were sparse and findings were inconsistent for visfatin, retinol 
Corresponding author: Dr. Cuilin Zhang, Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy 
Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6100 Executive Blvd, Rockville, 
MD 20852, USA; Phone/Fax: 301-435-6917; zhangcu@mail.nih.gov. 
Author contributions: WB and CZ designed the study and wrote the manuscript. AB and WB collected and analyzed the data. YS, 
MK, SL, and CZ interpreted the results and reviewed and edited the manuscript. W.B. and C.Z. had primary responsibility for final 
content. All authors provided intellectual input into the paper, and all authors read and approved the final manuscript.
Conflicts of interest: None.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Metabolism. Author manuscript; available in PMC 2016 June 01.
Published in final edited form as:













binding protein (RBP-4), resistin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and 
vaspin. We did not identify prospective studies for several novel adipokines, including chemerin, 
apelin, omentin, or adipocyte fatty acid-binding protein. Moreover, no published prospective 
studies with longitudinal assessment of adipokines and incident GDM were identified.
Conclusion—Adiponectin levels in the first or second trimester of pregnancy are lower among 
pregnant women who later develop GDM than non-GDM women, whereas leptin levels are 
higher. Well-designed prospective studies with longitudinal assessment of adipokines during 
pregnancy are needed to understand the trajectories and dynamic associations of adipokines with 
GDM risk.
Keywords
gestational diabetes mellitus; adipokines; adiponectin; leptin
1. INTRODUCTION
Gestational diabetes mellitus (GDM), a common pregnancy complication, is defined as 
glucose intolerance with onset or first recognition during pregnancy [1]. Approximately 7% 
(ranging from 1% to 14%) of all pregnancies in the United States are complicated by GDM, 
resulting in more than 200,000 cases annually [1]. Women with GDM have an increased risk 
for prenatal morbidity and a considerably elevated risk for type 2 diabetes mellitus (T2DM) 
after pregnancy [1]. Furthermore, the offspring of women with GDM are more likely to be 
obese and have impaired glucose tolerance and T2DM in their early adulthood [2].
Adiposity is an important modifiable risk factor for the development of GDM [3], although 
mechanisms linking excess adiposity to elevated risk of GDM are not completely 
understood. Adipose tissue is not only involved in energy storage but also functions as an 
active endocrine organ [4]. Recent evidence points to a crucial role of specific hormones and 
cytokines (i.e., adipokines) secreted by the adipose tissue. A major breakthrough in 
understanding the link between adiposity and glucose intolerance has come from the 
demonstration of crosstalk between adipose tissue and other insulin target tissues such as 
skeletal muscles and the liver [5]. Such crosstalk is mediated by a number of molecules that 
are secreted by adipocytes [4]. Among those identified to date are adiponectin, leptin, 
resistin, retinol binding protein 4 (RBP4), and tumor necrosis factor-α (TNF-α), etc. In 
concert, these adipokines are believed to adapt metabolic fluxes to the amount of stored 
energy. Dysregulation of this network is a critical factor in the deterioration of insulin 
sensitivity [4, 6].
Despite the promising role of these adipokines in glucose homeostasis, their roles in the 
development of GDM remain to be elucidated. Although there have been a number of 
human studies on adipokines and GDM during the past decades, inferences have been 
hindered due to significant heterogeneities in these studies concerning design, population 
characteristics, assay methods, timing of blood sample collection, and definition/diagnosis 
of GDM. Moreover, the majority of previous studies had a small sample size that may lead 
to false positive or negative findings. We aimed to systematically review the current 
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literature and quantitatively synthesize prospective data regarding adipokines and GDM risk, 
and to identify important data gaps.
2. MATERIALS AND METHODS
When conducting the study, we adhered to the Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) guidelines [7].
2.1 Literature search and study selection
We conducted a comprehensive electronic search of PubMed and EMBASE databases for 
literature on adipokines and GDM through October 21, 2014. To maximize the coverage in 
our literature search, we used a combination of free text (e.g., gestational diabetes) and 
subheadings from MeSH (e.g., “Diabetes, Gestational”[Mesh]) or EMTREE terms (e.g., 
‘pregnancy diabetes mellitus’/exp). In addition to using the generic term for adipokines, we 
also specifically named each key adipokine (e.g., adiponectin, leptin, resistin, etc.) when 
conducting the literature search. Detailed search terms are listed in the Supplementary 
Materials. We restricted the literature search to English language. All reference lists from 
the main articles and relevant reviews were hand searched to identify additional studies.
Figure 1 summarizes the process of literature search and study selection. Articles were 
eligible for inclusion if they had a prospective study design (i.e., blood samples for 
adipokines measurement were collected before the diagnosis of GDM, typically before 24 
weeks of gestational age), and they compared adipokine levels measured in pregnant women 
who later developed GDM with women with normoglycemic pregnancies. We excluded the 
following types of articles: review articles or editorials, non-human studies (i.e., cell culture 
or animal studies), studies that did not include GDM as the primary concern, and studies that 
did not evaluate adipokine levels. We also excluded articles that combined GDM with 
impaired glucose tolerance or previous cases of type 1 diabetes or T2DM. Disagreement 
about eligibility was settled by consensus between all authors.
2.2 Data extraction
The following data were extracted from each eligible article: the first author’s name, year of 
publication, sample size, number of GDM cases, ethnicity, study design, time for blood 
samples collected for adipokine measurement, method of adipokine measurement, time and 
criteria for GDM diagnosis, and mean and standard deviation (SD) of adipokine levels 
among GDM cases and the comparison group. When necessary, we contacted the 
corresponding authors of the original articles by email to request relevant data or 
information. We also extracted odds ratios, risk ratios, and 95% confidence intervals if they 
were available. If multiple articles were published using data from the same cohort, we 
extracted the report with the information most relevant to the analysis.
2.3 Data synthesis and statistical analysis
To quantitatively summarize the available data, we conducted meta-analyses for adipokines 
with more than five independent studies. We calculated weighted mean differences (WMDs) 
in adipokine levels for each of the included studies, and pooled them in the meta-analysis 
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using random-effects model [8]. We also calculated standardized mean differences (SMDs) 
when different units across studies were used for a certain adipokine. When means and SDs 
were not reported in the full-text article, we approximated them using the median and 
interquartile range. When applicable, the standard error of the mean was transformed into 
SD. Forest plots and funnel plots were used for visualizing the overall effect size and 
evaluating publication bias, respectively. The probability of publication bias was also 
statistically assessed using Egger regression asymmetry test [9].
We assessed between-study heterogeneity using the χ2-based Cochran’s Q statistic and the 
I2 metric (I2 value of 25, 50, and 75% were considered as low, medium, and high 
heterogeneity, respectively) [10]. Potential sources of between-study heterogeneity were 
also investigated by a priori-defined stratification analyses. Specifically, we stratified the 
included studies by geographical location, sample size, time for determination of exposure 
(i.e., adipokines) and outcome (i.e., GDM), assay methods for adipokines, and diagnostic 
criteria for GDM. A formal meta-regression was also performed by the aforementioned 
factors, but the potential for robust conclusions from meta-regression analyses may be very 
limited [11], because the number of included studies was small for some adipokines. 
Sensitivity analyses were performed by omitting one study at a time and computing the 
pooled the effect size of the remaining studies to evaluate whether the results were affected 
markedly by a single study. All statistical analyses were performed using Stata software 
version 11.0 (Stata Corp, College Station, TX, USA).
3. RESULTS
3.1 Characteristics of the included studies
Our initial literature search identified 1,523 articles from PubMed/MEDLINE and EMBASE 
databases. After applying the inclusion and exclusion criteria, 25 prospective studies [12–
36] on eight adipokines were ultimately included in the systematic review (Figure 1). These 
adipokines were adiponectin, leptin, visfatin, RBP-4, resistin, TNF-α, IL-6, and vaspin. 
Supplementary Table 1 summarizes the potential functions of these adipokines that may link 
them to the pathogenesis of GDM. In general, the number of prospective studies on GDM 
risk and these adipokines, except adiponectin and leptin, was sparse. We did not identify 
prospective studies relating several novel adipokines, such as chemerin, apelin, omentin, or 
adipocyte fatty acid-binding protein, to GDM risk.
Table 1 and Table 2 show characteristics of the 13 prospective studies about adiponectin and 
nine prospective studies about leptin, respectively. Overall, the reporting of the included 
studies was generally well described with sufficient details concerning key parameters such 
as the number of cases and controls, adipokine measurements (time for blood collection and 
assay method), and GDM diagnosis (time and criteria).
Among the 13 included studies for adiponectin, six studies were conducted in Europe, four 
in North America, two in Asia and one in Australia. Five studies used the criteria proposed 
by Carpenter and Coustan or the American Diabetes Association (ADA) (these two criteria 
used the same procedure and cut points) for the diagnosis of GDM, three studies used the 
World Health Organization (WHO) criteria, three studies used the recently proposed criteria 
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by the International Association of the Diabetes and Pregnancy Study Groups (IADPSG), 
and two used local criteria. GDM was usually diagnosed during the 24–28 weeks of 
gestation in these studies, with one exception. Blood samples for adiponectin measurement 
were collected at 5–20 weeks of gestation. No substantial differences were observed in the 
assay methods applied to measure adiponectin levels. The majority of included studies used 
enzyme immunoassays (EIA), while others employed radioimmunoassay (RIA). Several 
studies reported quality control measurements for adiponectin [15, 19, 20, 22, 23, 36], and 
the intra-assay and inter-assay coefficients of variation were acceptable (all < 10%).
Of the nine studies for leptin, three studies were conducted in North America, two in the 
Europe, two in Asia, one in Australia, and one in Mexico. GDM was usually diagnosed 
during the 24–28 weeks of gestation. The definition used for GDM was the criteria proposed 
by Carpenter and Coustan or the ADA in three studies, the IADPSG criteria in two studies, 
the National Diabetes Data Group criteria in one study, and local criteria in another two 
studies. Blood samples for leptin measurement were collected at 5–20 weeks of gestation. 
No substantial differences were observed in the methodology applied to assays; five studies 
used RIA, while the other four studies used EIA. Several studies reported quality control 
measurements for leptin [14, 16, 19, 26, 36], and the intra-assay and inter-assay coefficients 
of variation were acceptable (all < 10%).
3.2 Quantitative assessment of summary statistics
3.2.1 Adiponectin—Adiponectin was the most widely studied adipokines in relation to 
GDM, and the available studies yielded relatively consistent results across different 
populations. Among the included studies, three studies reported a comparable value but 
different unit of adiponectin (i.e., ng/ml in two studies [18, 21] and mg/ml in the other study 
[34]) compared with others (i.e., μg/ml), and thus the reported values were unreasonably 
high or low after converting. We did not get confirmation from the original authors by 
email. Thus, to be conservative, we did not include these studies in the main analysis which 
calculated the pooled WMD. Instead, we included them in a sensitivity analysis using 
pooled SMD as the metric. In another study [36], adiponectin levels were reported as 
geometric means and ratios, without values in the absolute scale, and therefore it was 
omitted in the meta-analysis. Our meta-analysis of the other nine studies showed that 
adiponectin levels in the first or early second trimester were significantly lower in women 
who later developed GDM compared to women who later did not, yet with significant 
between-study heterogeneity (random-effects pooled WMD [95% CI], −2.25 [−2.75 to 
−1.75] μg/ml; I2 = 86%; Figure 2). Egger test for publication bias did not reach statistical 
significance (P = 0.49).
In stratified analyses (Supplementary Table 2), the pooled WMDs were not differentiated 
appreciably by geographical location (North America versus others), sample size (< 100 
versus ≥100), average timing of blood samples collection for adiponectin measurement (first 
versus second trimester), assay methods for adiponectin measurement (EIA versus RIA), 
and diagnostic criteria for GDM (WHO criteria versus others). We did not stratify by time 
for GDM diagnosis because almost all included studies reported the diagnosis at 24–28 
weeks of gestation. Meta-regression analysis including the above variables in the model also 
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did not identify significant contributors to the source of heterogeneity. Sensitivity analysis 
by omitting one study at a time did not alter the results (Supplementary Figure 1). In 
addition, we calculated the pooled SMD which allows including the results from all studies 
regardless of units. The pooled random-effects SMD (95% CI) was −1.20 (−1.63 to −0.78) 
(Supplementary Figure 2).
3.2.2 Leptin—Among the nine studies, one study [36] reported leptin adiponectin levels as 
geometric means and ratios, without values in the absolute scale, and therefore it was 
omitted in the meta-analysis. A meta-analysis of the remaining eight prospective studies 
showed that leptin levels in the first or early second trimester were significantly higher in 
women who later developed GDM compared to women who later did not, yet with 
significant between-study heterogeneity (random-effects WMD [95% CI], 7.25 [3.27 to 
11.22] ng/ml; I2 = 94%; Figure 3). Egger test for publication bias did not provide evidence 
of significant effect (P = 0.41).
Similar to adiponectin, there was no evidence of heterogeneity in pooled WMDs for leptin 
levels by average timing of blood collection for leptin measurement (first versus second 
trimester), assay methods for leptin measurement (EIA versus RIA), and diagnostic criteria 
for GDM (Carpenter and Coustan criteria versus others) (Supplementary Table 3). 
Sensitivity analysis by omitting one study at a time did not alter the results materially 
(Supplementary Figure 3).
3.3 Findings of adipokines not suitable for a pooling of summary statistics
We did not pool studies that investigated visfatin, RBP-4, resistin, TNF-α, interleukin-6 
(IL-6), or vaspin, because too few independent prospective studies have been published on 
these adipokines. Findings on their association with GDM risk have been conflicting (Table 
3). For instance, three studies have been conducted about RBP-4 levels and GDM risk [28, 
29, 32]. Although a significant association was reported in a U.S. population [29], there was 
no significant association in other studies from UK [32] and China [28]. Conflicting results 
were also reported in the four studies about TNF-α levels and risk of GDM, with one study 
reporting a significant association [18] while another two reporting no significant 
association [12, 19, 35]. Recently, adipocyte fatty acid-binding protein (AFABP) has been 
suggested to be a probable candidate involved in the pathophysiology of GDM [37]. 
However, no prospective study has conducted so far on the association between AFABP and 
GDM. The only study, which was cross-sectional, reported an elevated AFABP level in 
women with GDM as compared with healthy pregnant controls [38].
4. DISCUSSION
In this systematic review and quantitative analysis of available data regarding adipokines 
and GDM, we observed that adiponectin levels in the first or second trimester of pregnancy 
are lower among pregnant women who later develop GDM than non-GDM women, whereas 
leptin levels are higher. Prospective data were sparse and findings were inconsistent for 
visfatin, RBP-4, resistin, TNF-α, IL-6, and vaspin. We did not identify prospective studies 
for several novel adipokines, including chemerin, apelin, omentin, or AFABP.
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The observed associations of GDM with adiponectin and leptin levels are biologically 
plausible. GDM develops when pancreatic β cells of pregnant women are unable to increase 
insulin secretion enough to counteract the corresponding fall in tissue sensitivity to insulin 
during pregnancy [39]. Adiponectin is a signaling protein that is synthesized and secreted by 
adipose tissue and is one of the most abundant plasma proteins in humans [40]. Adiponectin 
can reduce ectopic fat storage through stimulating lipid oxidation and inhibiting lipolysis in 
adipose tissue [41]. In addition, adiponectin may also display anti-inflammatory properties 
by suppressing TNF-α production [42]. Intravenous administration of recombinant 
adiponectin in rodent models of insulin resistance restored normal insulin sensitivity [6]. In 
humans, adiponectin levels were inversely associated with fasting glucose, insulin, and 
insulin resistance [43], and the risk of developing T2DM [44]. Thus, a reduction in 
adiponectin levels may be associated with the development of GDM through decreased 
insulin sensitivity and attenuated anti-inflammatory capacity.
In contrast to adiponectin, leptin may contribute to the pathogenesis of GDM through 
elevated insulin resistance. Leptin is an adipose tissue-derived hormone that plays a key role 
in the regulation of energy intake and energy expenditure. Circulating leptin levels are 
elevated with increasing adiposity [45], reflecting a state of leptin resistance [46]. Several 
studies have positively associated leptin levels with insulin resistance independent of body 
mass index (BMI), whereas other studies suggest that the relationship between leptin levels 
and insulin resistance is mainly accounted for by obesity [47, 48]. Elevated leptin levels 
were also independently associated with a higher risk of incident GDM [14] and T2DM 
[49]. Animal and human studies have demonstrated that a circulating soluble form of the 
leptin receptor influences the amount of free versus bound leptin in serum and plays a part in 
modulating availability and biological function of leptin [50]. In humans, an increasing BMI 
was associated with a lower concentration of soluble leptin receptor, whereas fasting 
increased its concentration [51]. Lewandowski et al [52] reported a significantly higher level 
of soluble leptin receptor in women with type 1 diabetic pregnancy than women with normal 
pregnancy. However, there is no published study on the association between soluble leptin 
receptor and GDM.
Interestingly, there is evidence, although still limited, implicating that the association 
between adipokines and GDM may be independent of adiposity measures. For example, 
Williams et al [15] have shown a significantly inverse association between adiponectin 
levels in early pregnancy and subsequent risk of GDM after controlling for prepregnancy 
BMI. Similar results were reported by Lain et al [20] and LaCroix et al [31]. For leptin, Qiu 
et al [14] found a linear association between leptin levels in early pregnancy and GDM risk 
independent of prepregnancy BMI and other confounders; each 10 ng/mL increase in the 
leptin concentration was associated with a 20% higher in GDM risk. These results indicate 
that there could be other pathways linking adipokines to the development of GDM, although 
BMI is not an accurate measure of adiposity [53]. Future studies using objective measures of 
adiposity (e.g., dual-energy X-ray absorptiometry) may help clarify the adipokines-GDM 
relations independent of adiposity. Few studies have investigated the interaction between 
adiposity measures and adipokines among pregnancy women. No significant interaction 
between BMI and adiponectin in association with risk of developing GDM was found in a 
nested case-control study among US pregnant women [20]. Similarly, non-significant 
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interactions of adiposity measures and adiponectin levels in relation to T2DM risk were 
observed in some [54], although not all [55], studies conducted in the general population.
There are several critical data gaps that require additional research. First, the trajectories and 
dynamic associations of adipokines with subsequent risk of GDM remain unclear. Unlike 
diabetes among non-pregnant individuals, the dynamic patterns of adipokine levels in 
women with GDM are influenced not only by GDM status, but also by the profound and yet 
time-dependent metabolic challenges related to pregnancy. Pregnancy is normally associated 
with progressive insulin resistance, and there is a two-thirds decrease in insulin sensitivity in 
late pregnancy [39]. In parallel with the changes in insulin sensitivity, adipokines exhibit 
different dynamic patterns during normal pregnancy [56]. For instance, adiponectin levels 
progressively decline [57] while leptin levels progressively increase during pregnancy [58]. 
Longitudinal studies with blood samples collected at multiple time points before the onset of 
GDM (e.g., before pregnancy or during early pregnancy) would provide insights to improve 
understanding of the roles of adipokines in the pathogenesis of GDM. No such study was 
identified in our systematic review. Second, the causal relation between adipokines and 
GDM warrants further investigation. During the past decades, Mendelian randomization 
analysis simultaneously considering the triangle associations of genetic variants, 
intermediate phenotypes, and disease status has been increasingly utilized to inform causal 
inference in observational studies [59]. However, we are not aware of such studies 
investigating associations of both adipokine levels and genetic variants relevant to adipokine 
levels with GDM risk using Mendelian randomization analysis approach.
The strengths of this systematic review include comprehensive literature search and 
meticulous protocol for study selection and data analysis. There are several limitations. First, 
prospective studies of adipokines and GDM risk among non-Caucasian populations are 
sparse. This limited the capacity of exploring the adipokines-GDM association by race/
ethnicity groups. Compared with Caucasian women, Asian, Hispanic, and Native American 
women have an increased risk of GDM [3]. In addition, the associations between adipokines 
and insulin sensitivity varied by race/ethnicity [60]. Future studies among non-Caucasian 
populations are warranted. Second, the number of included studies for most adipokines was 
small. Even for adiponectin and leptin, the pooled sample size was limited. Thus it may 
compromise the statistical power of the meta-analysis. Although the statistical test showed 
no indication of publication bias for the two adipokines included in the meta-analysis, we 
cannot rule out the possibility of publication bias due to the small number of studies.
5. Conclusions
In summary, in this systematic review, we observed that adiponectin levels in the first or 
second trimester of pregnancy are lower among pregnant women who later develop GDM 
than non-GDM women, whereas leptin levels are higher. Future studies are warranted to 
clarify the association of other adipokines and GDM. Moreover, well-designed prospective 
studies with longitudinal assessment of adipokines during pregnancy are needed to 
understand the trajectories and dynamic associations of adipokines with GDM risk.
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Flow chart for literature search and study selection
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Forest plot for mean difference in adiponectin levels (μg/ml) between GDM cases and 
controls
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Forest plot for mean difference in leptin levels (ng/ml) between GDM cases and controls
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Table 3
Summary of the results from available prospective studies relating adipokine levels to GDM risk
Adipokines Number of studies Results*
Adiponectin 13 ↑ 0 study, ↓ 12 studies, ↔ 1 study
Leptin 9 ↑ 4 studies, ↓ 0 study, ↔ 5 studies
Visfatin 2 ↑ 1 study, ↓ 0 study, ↔ 1 study
RBP-4 3 ↑ 1 study, ↓ 0 study, ↔ 2 studies
Resistin 2 ↑ 0 study, ↓ 0 study, ↔ 2 studies
TNF-α 4 ↑ 1 study, ↓ 0 study, ↔ 3 studies
IL-6 3 ↑ 0 study, ↓ 0 study, ↔ 3 studies
Vaspin 1 ↑ 1 study, ↓ 0 study, ↔ 0 study
*
↑ positive association, ↓ inverse association, ↔ non-significant difference (p > 0.05)
Abbreviations: IL-6, interleukin-6; RBP-4, retinol binding protein-4; TNF-α, tumor necrosis factor-α.
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